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THE EVALUATION OF THE COMPLICATIONS, SURVIVAL AND CAUSES OF 
DEATH IN PATIENTS WITH PHILADELPHIA CHROMOSOME NEGATIVE 
MYELOPROLIFERATIVE DISORDERS   
 
SUMMARY 
 
Philadelphia chromosome negative myeloproliferative disorders are a clonal 
hematological disorders which are characterised by frequently secondary myelofibrosis and 
rarely leukemic transformation. Myeloproliferative disorders are a disease of pluripotent 
hematopoetic stem cell, and with the abnormal proliferation of the hematopoetic cell series 
progenitors granulocyte, erythrocyte or platalet count increase.  
This study was performed in the Department of Internal Medicine, Division of 
Hematology of Adnan Menderes University Medical Faculty, AYDIN.  In retrospective study, 
we evaluated the thromboembolic and hemorrhagic complications, the development of the 
secondary myelofibrosis and leukemic transformation, survival, factors affecting survival, 
causes of death, the significiance of the JAK2 mutation in the the diagnosis and complications 
in Philadelphia chromosome negative 104 myeloproliferative disorders patients.  
Totaly 104 patients were included in the study and 54 of them (52%) were male. Mean 
age of the patients was 59±16 years (range 17-84). The distribituion of myeloproliferative 
disorders were essential thrombocythemia in 58%, polycythemia vera in 24%), and primary 
myelofibrosis in 18%. On physical examination, the most common findings were 
splenomegaly (46%), hepatomegaly (46%), pallor (28%), and eryhtromelalgia (14%). The 
most common complications were hemorrhage (50%), and thromboembolic events (42%). 
Secondary myelofibrosis and leukemic transformation were seen in the patients of 5% and 
1%, respectively.     
JAK 2 mutation was positive in forty-six patients (70%) of the 66 patient whose 
mutation was evaluated. The positivities of JAK2 mutation were 83% of patients with 
polycythemia vera, 61% of patients with essential thrombocythemia, and 80% of patients with 
primary myelofibrosis. Causes of death were thromboembolism (45%), disease progression 
(18%), respiratory insufficiency (14%), and other reasons (23%) in the patients with 
myeloproliferative disorders. Risk factors for thromboembolism were leukocytosis (p=0.003) 
and advanced age (p < 0.005). When used logistic regression, it was found that these two 
factors were significiant factors for theromboembolism (p values were respectively 0.027 and 
0.025). Leukocyte count in the patients with JAK2 mutation was higher than those with 
negative ( p=0.005). There was not a difference for JAK2 positivity between patients with 
thromboembolism and without thromboembolism (p>0.05). Also there was not a significiant 
factor on hemorrhagic complications when used logistic regression analysis. The JAK2 
mutation and platelet count had no effect on thromboembolism and survival. Mean survival 
time was significantly different between patients treated with aspirin and without (p<0.0001). 
Hydroxiurea was the most commonly used drug in myeloproliferative disorders. When 
performed Kaplan-Meier analysis, mean survival time was detected as 146±14 months in the 
patients with PV, 114±7 months in those with essential thrombocythemia, and 125±34 months 
in those with primary myelofibrosis, respectively.  Mean survival time in patients with all 
myeloproliferative disorders were 157±20 months. However there was not a difference 
between groups for survival time.  
In conclusion, thromboembolism and hemorrhagic complications were frequently seen 
in myeloproliferative disorders. Only leukocyte count and advanced age had effect on 
thromboembolic complications. While the diagnosis of myeloproliferative disorders have no 
effect on survival, thromboembolic events and the use of aspirin were significiant factors 
affecting survival time. For this reason, teh use of aspirin is an important issue to prevent 
thromboembolic events and to improve survival time. 
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